Ocean Biomedical is a biotechnology business based in the US. Ocean Biomedical shares (OCEA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.05 – a decrease of 18.91% over the previous week.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.05 |
|---|---|
| 52-week range | $0.05 - $3.85 |
| 50-day moving average | $0.94 |
| 200-day moving average | $1.54 |
| Wall St. target price | $18.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.053 from 2025-04-02
| 1 week (2025-03-28) | -17.19% |
|---|---|
| 1 month (2025-03-04) | -37.65% |
| 3 months (2025-01-03) | -92.73% |
| 6 months (2024-10-04) | -94.18% |
| 1 year (2024-04-04) | -98.03% |
|---|---|
| 2 years (2023-04-04) | -98.97% |
| 3 years (2022-04-04) | 10.09 |
| 5 years (2020-03-31) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -681.99% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $-2.21 |
| Market Capitalization | $25.6 million |
TTM: trailing 12 months
We're not expecting Ocean Biomedical to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Ocean Biomedical's shares have ranged in value from as little as $0.051 up to $3.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ocean Biomedical's is 1.529. This would suggest that Ocean Biomedical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Ocean Biomedical's beta into context you can compare it against those of similar companies.
Ocean Biomedical, Inc. , a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome. It is also developing three product candidates based on the whole proteome differential screening target discovery platform, including a malaria vaccine candidate against plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1) and/or against plasmodium falciparum Glutamic Acid Rich Protein (PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria product candidate targeting PfGARP. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Here’s the scoop on Ark7, what it is and how it works.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
A deep dive into the highlights and limitations of Robinhood.